LongBio Pharma

LongBio Pharma (Suzhou/Shanghai, founded 2020) is a Chinese clinical-stage biopharmaceutical company focused on the in-house discovery and development of innovative antibody and fusion-protein therapeutics for allergic, autoimmune, and complement-mediated diseases. Its lead programs include the anti-IgE antibody LP-003 for chronic spontaneous urticaria and asthma. Co-founded by Dr. Bill Nai-chau Sun (co-founder of Tanox and co-inventor of Omalizumab/Xolair), LongBio raised a Series B2 round led by Qiming Venture Partners and listed on the Hong Kong Stock Exchange (01779.HK) in June 2026. It is a pharmaceutical drug developer with no public developer or API surface; this profile was surfaced as a Qiming portfolio company and completed an enrichment pass.

LongBio Pharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Healthcare, and Drug Discovery.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyPharmaceuticalsBiotechnologyHealthcareDrug DiscoveryAntibodiesAutoimmuneAllergy

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/longbio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website

Website

LinkedIn

Source (apis.yml)

aid: longbio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/longbio.png
name: LongBio Pharma
description: LongBio Pharma (Suzhou/Shanghai, founded 2020) is a Chinese clinical-stage biopharmaceutical company focused
  on the in-house discovery and development of innovative antibody and fusion-protein therapeutics for allergic, autoimmune,
  and complement-mediated diseases. Its lead programs include the anti-IgE antibody LP-003 for chronic spontaneous urticaria
  and asthma. Co-founded by Dr. Bill Nai-chau Sun (co-founder of Tanox and co-inventor of Omalizumab/Xolair), LongBio raised
  a Series B2 round led by Qiming Venture Partners and listed on the Hong Kong Stock Exchange (01779.HK) in June 2026. It
  is a pharmaceutical drug developer with no public developer or API surface; this profile was surfaced as a Qiming portfolio
  company and completed an enrichment pass.
url: https://raw.githubusercontent.com/api-evangelist/longbio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Healthcare
- Drug Discovery
- Antibodies
- Autoimmune
- Allergy
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.longbio.com
- type: LinkedIn
  url: https://www.linkedin.com/company/longbio
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1